These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11856863)

  • 1. Microvascular complications in cystic fibrosis-related diabetes mellitus: a case report.
    Scott AI; Clarke BE; Healy H; D Emden M; Bell SC
    JOP; 2000 Nov; 1(4):208-10. PubMed ID: 11856863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications.
    Andersen HU; Lanng S; Pressler T; Laugesen CS; Mathiesen ER
    Diabetes Care; 2006 Dec; 29(12):2660-3. PubMed ID: 17130201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular complications in cystic fibrosis-related diabetes.
    Schwarzenberg SJ; Thomas W; Olsen TW; Grover T; Walk D; Milla C; Moran A
    Diabetes Care; 2007 May; 30(5):1056-61. PubMed ID: 17322485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
    Hayes D; Kanga JF; Anstead MI; Kuhn RJ
    Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver disease as risk factor for cystic fibrosis-related diabetes development.
    Minicucci L; Lorini R; Giannattasio A; Colombo C; Iapichino L; Reali MF; Padoan R; Calevo MG; Casciaro R; De Alessandri A; Haupt R
    Acta Paediatr; 2007 May; 96(5):736-9. PubMed ID: 17381470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti Pseudomonas aeruginosa antibiotic therapy in cystic fibrosis (exclusion of macrolides)].
    Sermet-Gaudelus I; Ferroni A; Vrielinck S; Lebourgeois M; Chedevergne F; Lenoir G
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S30-43. PubMed ID: 17370394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).
    van den Berg JM; Morton AM; Kok SW; Pijl H; Conway SP; Heijerman HG
    J Cyst Fibros; 2008 Nov; 7(6):515-9. PubMed ID: 18619927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
    Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
    Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes mellitus and bone disease in cystic fibrosis.
    Curran DR; McArdle JR; Talwalkar JS
    Semin Respir Crit Care Med; 2009 Oct; 30(5):514-30. PubMed ID: 19760539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside ototoxicity susceptibility in cystic fibrosis.
    Mulrennan SA; Helm J; Thomas RB; Dodd M; Jones A; Webb K
    Thorax; 2009 Mar; 64(3):271-2. PubMed ID: 19252031
    [No Abstract]   [Full Text] [Related]  

  • 14. Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes.
    Tierney S; Deaton C; Webb K; Jones A; Dodd M; McKenna D; Rowe R
    J Clin Nurs; 2008 Apr; 17(7B):235-43. PubMed ID: 18578799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis.
    Jarad NA; Giles K
    Chron Respir Dis; 2008; 5(1):29-33. PubMed ID: 18303099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of β-lactams as single agents for treating severe pulmonary exacerbations during pregnancy in cystic fibrosis.
    Prickett M; Jain M
    Am J Respir Crit Care Med; 2012 Dec; 186(12):1310-1. PubMed ID: 23250504
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment.
    Festini F; Ciuti R; Taccetti G; Repetto T; Campana S; De Martino M
    J Matern Fetal Neonatal Med; 2006 Jun; 19(6):375-6. PubMed ID: 16801316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic-related renal failure and cystic fibrosis.
    Kennedy SE; Henry RL; Rosenberg AR
    J Paediatr Child Health; 2005 Jul; 41(7):382-3. PubMed ID: 16014148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis related diabetes.
    Zirbes J; Milla CE
    Paediatr Respir Rev; 2009 Sep; 10(3):118-23; quiz 123. PubMed ID: 19651382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A liposome model to treat pseudomonas in lungs of cystic fibrosis and immune compromised patients.
    Yatvin MB
    Cell Mol Biol Lett; 2002; 7(2):304. PubMed ID: 12097974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.